Ascletis Pharma
Latest round
- Series B
Last raised
- Jan 2017
Total raised
- $100M
Investors
- 6
About Ascletis Pharma
Founded in 2013 and based in Hangzhou, China, Ascletis Pharma Inc. operates as a pharmaceutical company which focuses on developing and manufacturing drugs in 3 areas, that is anti-viral (especially anti-HIV), cancer and fatty liver disease. The company has set up a production base in Shaoxing which has acquired drug production licence. The CFO, John P. Gargiulo, graduted from Duke University. It has cooperated with Roche Holding. In January 2017, Ascletis Pharma Inc. In 2018, it was listed on the Hong Kong Stock Exchange. Ascletis focuses on the research, development and commercialization of innovative drugs in the fields of viral diseases, metabolic diseases, tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors). Products include Gonovo, Ravidasvir and ASC21, etc. The company generates revenue by developing innovative drugs for the treatment of diseases such as antiviral, cancer and fatty liver.
Who invested in Ascletis Pharma
6 investors across 1 round
See all investors in Ascletis Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 3, 2017
Amount
$100M
Investors
Questions about Ascletis Pharma
Who invested in Ascletis Pharma?
Ascletis Pharma has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ascletis Pharma raised?
Ascletis Pharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ascletis Pharma last raise money?
Ascletis Pharma's most recent round on record is a Series B, in Jan 2017.
What does Ascletis Pharma do?
Founded in 2013 and based in Hangzhou, China, Ascletis Pharma Inc.
Where is Ascletis Pharma headquartered?
Ascletis Pharma is headquartered in Hangzhou, China.
Which VCs invest in companies like Ascletis Pharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Ascletis Pharma's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Ascletis Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.